Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;80(14):1485-1490.
doi: 10.1007/s40265-020-01386-w.

Fostemsavir: First Approval

Anthony Markham  1
Affiliations
Review

Fostemsavir: First Approval

Anthony Markham. Drugs. 2020 Sep.

Erratum in

Abstract

Fostemsavir (Rukobia), a prodrug of the HIV-1 attachment inhibitor temsavir, is a first-in-class treatment for HIV infection being developed by ViiV Healthcare. Based on the results of the phase III BRIGHTE trial fostemsavir was recently approved in the USA for the treatment of patients with HIV not able to be treated with other therapies. This article summarizes the milestones in the development of fostemsavir leading to this first approval.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. US Food & Drug Administration. FDA approves new HIV treatment for patients with limited treatment options [media release]. 2 July 2020. https://www.fda.gov .
    1. US Food & Drug Administration. Rukobia (fostemsavir): US prescribing information. 2020. https://www.accessdata.fda.gov . Accessed 31 July 2020.
    1. ViiV Healthcare. ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available [media release]. 10 Jan 2020. https://www.viivhealthcare.com .
    1. Bristol-Myers Squibb. Bristol-Myers Squibb completes previously announced sale of its HIV R portfolio to ViiV Healthcare [media release]. 2016. https://www.bms.com .
    1. Pancera M, Lai YT, Bylund T, et al. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017;13(10):1115–22. - DOI

LinkOut - more resources